News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street Zen has downgraded Fortress Biotech (NASDAQ:FBIO) from a "strong-buy" to a "hold" rating. The stock currently holds an average "Hold" rating among analysts with a consensus price target of $17.00. Fortress Biotech recently reported stronger-than-expected quarterly earnings, with EPS of -$0.08 and …
This article analyzes Fortrea Holdings Inc. (FTRE) using AI models, highlighting a mid-channel oscillation and divergent sentiment across time horizons, suggesting choppy conditions. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides …
SmartRent, Inc.'s General Counsel, Brian Michael McQuaid, converted 28,435 Restricted Stock Units (RSUs) into an equal number of Class A Common Stock shares on August 14, 2026. Following this transaction, McQuaid directly holds 39,817 shares of Class A Common Stock, which includes shares acquired …
This article reports on a Form 8K filing by VirTra Inc. for August 14th. The filing is a standard disclosure document used by public companies to announce major events or changes. The article provides the title of the filing and its publication date.
This article is a placeholder for Fortress Biotech's Q2 earnings snapshot. It currently contains no detailed financial information or an actual earnings report. The provided content is minimal and primarily consists of privacy protection disclaimers.
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%VirTra (VTSI) reported Q2 2026 revenue of $5.8 million, with a GAAP net loss of $0.3 million, or $0.02 loss per diluted share. For the first six months of 2026, revenue was $9.2 million and net loss was $1.6 million. The company's backlog stood …
Assenagon Asset Management S.A. significantly increased its stake in Fortrea Holdings Inc. by 90.7% in Q2 2026, now owning 173,129 shares valued at $3.0 million. This comes as Fortrea reported strong quarterly results, beating EPS and revenue estimates, while analysts maintain a "Hold" rating …
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%Fortress Biotech reported a consolidated net income of $137.8 million for the first half of 2026, primarily due to a $158.9 million gain from the sale of a Rare Pediatric Disease priority review voucher by its subsidiary Cyprium. This sale significantly boosted the company's …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%VirTra Inc. reported a 17% year-over-year revenue decrease to $5.8 million in Q2 2026, primarily due to timing delays in domestic deliveries. Despite this, bookings rose to $5.5 million, and the company achieved a positive Adjusted EBITDA of $0.4 million for the quarter. The …
VirTra (NASDAQ: VTSI) reported a second-quarter EPS of $-0.020, significantly beating analyst estimates of $-0.110 by $0.09. The company's revenue also surpassed expectations, coming in at $5.8M against a consensus estimate of $3.54M. Despite a strong earnings beat, VirTra's stock has seen fluctuations, being …
Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …
VirTra Inc. reported better-than-expected Q2 2026 results, with a smaller loss and revenue significantly exceeding Wall Street estimates, leading to a rise in after-hours trading. The company's revenue increased 65.7% sequentially due to stronger conversion and international sales, though gross margin decreased. Management highlighted …
Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …
VirTra, Inc. (VTSI) reported a Q2 loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a $0.09 loss and representing a 77.78% earnings surprise. The company also exceeded revenue estimates, posting $5.76 million against an expectation of $3.49 million, though this was …
Long Pond Capital, LP, Long Pond Capital GP, LLC, and John Khoury have reported a beneficial ownership of 5,610,150 shares of SmartRent, Inc.'s Class A common stock, representing 2.91% of the class. This ownership is held with shared voting and shared dispositive power, and …
Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …
VirTra (Nasdaq: VTSI) announced its financial results for Q2 and the first six months of 2026, reporting a 17% year-over-year revenue decrease to $5.8 million in Q2 and a net loss of $0.3 million. Despite the revenue decline, the company achieved $5.5 million in …
SmartRent director Thomas N. Bohjalian recently purchased 5,000 shares of the company's Class A Common Stock for $6,700, increasing his beneficial ownership to 726,062 shares. This insider transaction follows positive momentum for SMRT stock and comes after SmartRent reported a 4% increase in revenue …
SmartRent, Inc. director Thomas N. Bohjalian purchased 5,000 shares of Class A Common Stock on August 11, 2026, at a price of $1.34 per share in an open-market transaction. Following this purchase, Bohjalian directly holds 726,062 shares of SmartRent common stock. The transaction was …
Fortrea (NASDAQ:FTRE) shares fell 5.4% during midday trading despite beating quarterly earnings and revenue expectations. Analyst sentiment for the stock remains mixed, with a consensus "Hold" rating and an average price target of $20.75. The company's CEO also recently sold nearly 100,000 shares to …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 11:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Kelly Reisdorf President and Chief Executive Officer - Frank Martell Chief Financial Officer - Daryl Stemm Full Conference Call Transcript Operator: Hello everyone, …
Analysts have issued a "Hold" consensus recommendation for Fortrea Holdings Inc. (NASDAQ:FTRE), with an average 12-month price target of $20.75. The company recently reported strong quarterly results, exceeding EPS and revenue expectations. CEO Anshul Thakral sold shares to cover tax obligations, and institutional investors …
SmartRent CEO Frank Martell acquired 100,000 shares of the company's Class A Common Stock for $142,260 on August 11, 2026. This purchase increases his indirect holdings to over 3.6 million shares through his family trust. The acquisition follows SmartRent's recent Q2 financial results, which …
Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …
Search by ticker symbol or company name and select a result to open its chart.